4D Molecular Therapeutics to Participate in Chardan’s 5th Annual Genetic Medicines Conference

Rhea-AI Summary

4D Molecular Therapeutics (Nasdaq: FDMT) will participate in Chardan's 5th Annual Genetic Medicines Conference on October 4, 2021, at 2:30 p.m. ET. This virtual event will feature a fireside chat format, offering insights into the company's advancements in gene therapy. A live webcast will be accessible on the 4DMT website, with a replay available for two weeks post-event. 4DMT utilizes directed evolution to develop targeted gene therapies focusing on ophthalmology, cardiology, and pulmonology, currently conducting clinical trials for three product candidates.

EMERYVILLE, Calif., Sept. 29, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that management will participate in Chardan’s 5^th Annual Genetic Medicines Conference being held virtually on Monday, October 4. Details of the fireside chat are as follows:

Event: Chardan’s 5^th Annual Genetic Medicines Conference

Date & Time: Monday, October 4, 2021 at 2:30 p.m. ET

Format: Fireside Chat

A live audio webcast of the fireside chat will be available by visiting the “Investors & Media” section of the 4DMT website at www.4dmoleculartherapeutics.com. A replay of the webcast will be available for at least two weeks following the live event.

About 4DMT

4DMT is a clinical-stage company harnessing the power of directed evolution for targeted gene therapies. 4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector Evolution, which combines the power of directed evolution with approximately one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products. The company is initially focused in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The 4DMT targeted and evolved vectors are invented with the goal of being delivered through clinically routine, well-tolerated and minimally invasive routes of administration, transducing diseased cells in target tissues efficiently, having reduced immunogenicity and, where relevant, having resistance to pre-existing antibodies. 4DMT is currently conducting three clinical trials: 4D-125 is in a Phase 1/2 clinical trial for XLRP patients, 4D-110 is in a Phase 1 clinical trial for choroideremia patients and 4D-310 is in a Phase 1/2 clinical trial for Fabry disease patients.

4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.

4D-310, 4D-125 and 4D-110 are our product candidates in clinical trials and have not yet been approved for marketing by the US FDA or any other regulatory authority. No representation is made as to the safety or effectiveness of 4D-310, 4D-125, or 4D-110 for the therapeutic use for which they are being studied.

Contacts:

Media:

Carolyne Zimmermann
Chief Business Officer
czimmermann@4dmt.com

Investors:

Mike Zanoni
VP, Investor Relations
mzanoni@4dmt.com

FAQ

What is the date and time of the FDMT fireside chat at the Chardan conference?

The 4D Molecular Therapeutics fireside chat will take place on October 4, 2021, at 2:30 p.m. ET.

Where can I watch the FDMT fireside chat?

The fireside chat can be watched live on the Investors & Media section of the 4D Molecular Therapeutics website.

What is the focus of 4D Molecular Therapeutics?

4D Molecular Therapeutics focuses on targeted gene therapies in ophthalmology, cardiology, and pulmonology.

What clinical trials is FDMT currently conducting?

FDMT is conducting clinical trials for three product candidates: 4D-125 for XLRP, 4D-110 for choroideremia, and 4D-310 for Fabry disease.

How long will the replay of the FDMT fireside chat be available?

The replay of the fireside chat will be available for at least two weeks following the live event.